Optimal Targeting Agents: Choosing Between Antibodies & Ligands to Maximize Efficacy & Overcome Delivery Challenges

• Analyzing differential cellular processing of antibodies versus ligands to guide therapeutic strategy
• Comparing biodistribution of antibodies versus ligands to optimize target delivery
• Identifying opportunities for synergistic efficacy to enhance treatment outcomes

Speakers:

Neil H.

Founder and Scientific Chief and Officer

Convergent Therapeutics